Identifying Biomarkers for Risk of Premature Menopause Among Childhood Cancer Survivors May Lead to Targeted Interventions and Wellness Strategies
Menée auprès de 799 femmes ayant survécu à un cancer pédiatrique, cette étude identifie, à l'aide d'une étude d'association sur le génome entier, un haplotype associé fortement à la survenue, avant l'âge de 40 ans, d'une ménopause liée aux traitements anticancéreux gonadotoxiques
Female survivors of childhood cancer are at risk of late effects of their cancer treatment including increased risk of premature menopause before age 40 years (1). Premature menopause causes infertility at an early age, and also is linked to other adverse health outcomes such as heart disease and osteoporosis (2). Identifying biomarkers that define risk strata for treatment-associated premature menopause may allow survivors to partake in targeted medical interventions aimed to reduce or prevent the consequences of premature menopause, such as fertility preservation procedures and prevention programs for cardiovascular diseases and osteoporosis.
Journal of the National Cancer Institute , éditorial, 2017